Circulating IL-35 in pancreatic ductal adenocarcinoma patients

Human Immunology

Volumn 75, Issue 1, 2014, Pages 29-33

  Jin, Peng ^a   Ren, He ^a   Sun, Wei ^a   Xin, Wen ^a   Zhang, Huan ^a   Hao, Jihui ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 35; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EBI3; EPSTEIN-BARR VIRUS-INDUCED GENE 3; PANCREATIC DUCTAL ADENOCARCINOMA; PBMCS; PDAC; PERIPHERAL BLOOD MONONUCLEAR CELLS; REGULATORY T-CELLS; TREGS;

AGED; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERLEUKIN-12 SUBUNIT P35; INTERLEUKINS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; RNA, MESSENGER;

EID: 84890170920     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.09.018     Document Type: Article

References (37)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11.
2. Steele C.W., Jamieson N.B., Evans T.R., McKay C.J., Sansom O.J., Morton J.P. Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer 2013, 108:997.
3. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137.
4. Dinarello C.A. Interleukin-1beta and the autoinflammatory diseases. N Engl J Med 2009, 360:2467.
5. Boraschi D., Dinarello C.A. IL-18 in autoimmunity: review. Eur Cytokine Netw 2006, 17:224.
6. Dinarello C.A. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev 2006, 25:307.
7. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566.
8. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5:263.
9. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005, 6:345.
10. Liyanage U.K., Moore T.T., Joo H.G., Tanaka Y., Herrmann V., Doherty G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169:2756.
11. Yamamoto T., Yanagimoto H., Satoi S., Toyokawa H., Hirooka S., Yamaki S., et al. Circulating CD4+CD25+regulatory T cells in patients with pancreatic cancer. Pancreas 2012, 41:409.
12. Niedbala W., Wei X.Q., Cai B., Hueber A.J., Leung B.P., McInnes I.B., et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007, 37:3021.
13. Collison L.W., Pillai M.R., Chaturvedi V., Vignali D.A. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol 2009, 182:6121.
14. Huang C.H., Loo E.X., Kuo I.C., Soh G.H., Goh D.L., Lee B.W. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. J Immunol 2011, 187:462.
15. Wirtz S., Billmeier U., McHedlidze T., Blumberg R.S., Neurath M.F. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology 2011, 141:1875.
16. Kochetkova I., Golden S., Holderness K., Callis G., Pascual D.W. IL-35 stimulation of CD39+regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 2010, 184:7144.
17. Bardel E., Larousserie F., Charlot-Rabiega P., Coulomb-L'Hermine A., Devergne O. Human CD4+CD25+Foxp3+regulatory T cells do not constitutively express IL-35. J Immunol 2008, 181:6898.
18. Collison L.W., Chaturvedi V., Henderson A.L., Giacomin P.R., Guy C., Bankoti J., et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010, 11:1093.
19. Collison L.W., Vignali D.A. Interleukin-35: odd one out or part of the family?. Immunol Rev 2008, 226:248.
20. Devergne O., Birkenbach M., Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A 1997, 94:12041.
21. Devergne O., Hummel M., Koeppen H., Le Beau M.M., Nathanson E.C., Kieff E., et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 1996, 70:1143.
22. Mao H., Gao W., Ma C., Sun J., Liu J., Shao Q., et al. Human placental trophoblasts express the immunosuppressive cytokine IL-35. Hum Immunol 2013, 74:872.
23. Nishino R., Takano A., Oshita H., Ishikawa N., Akiyama H., Ito H., et al. Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res 2011, 17:6272.
24. Long J., Zhang X., Wen M., Kong Q., Lv Z., An Y, et al. IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochem Biophys Res Commun 2013, 430:364.
25. Wang Z., Liu J.Q., Liu Z., Shen R., Zhang G., Xu J., et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol 2013, 190:2415.
26. Callery M.P., Chang K.J., Fishman E.K., Talamonti M.S., William Traverso L., Linehan D.C. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009, 16:1727.
27. Gonin J., Larousserie F., Bastard C., Picquenot J.M., Couturier J., Radford-Weiss I., et al. Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma. PLoS ONE 2011, 6:e24617.
28. Larousserie F., Bardel E., Pflanz S., Arnulf B., Lome-Maldonado C., Hermine O. Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am J Pathol 2005, 166:1217.
29. Lin Y., Huang Y., Lu Z., Luo C., Shi Y., Zeng Q., et al. Decreased plasma IL-35 levels are related to the left ventricular ejection fraction in coronary artery diseases. PLoS ONE 2012, 7:e52490.
30. Pflanz S., Timans J.C., Cheung J., Rosales R., Kanzler H., Gilbert J. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002, 16:779.
31. Allan S.E., Song-Zhao G.X., Abraham T., McMurchy A.N., Levings M.K. Inducible reprogramming of human T cells into Treg cells by a conditionally active form of Foxp3. Eur J Immunol 2008, 38:3282.
32. Seyerl M., Kirchberger S., Majdic O., Seipelt J., Jindra C., Schrauf C., et al. Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. Eur J Immunol 2010, 40:321.
33. Ye S., Wu J., Zhou L., Lv Z., Xie H., Zheng S. Interleukin-35: the future of hyperimmune-related diseases?. J Interferon Cytokine Res 2013, 33:285.
34. Green E.A., Choi Y., Flavell R.A. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 2002, 16:183.
35. Green E.A., Gorelik L., McGregor C.M., Tran E.H., Flavell R.A. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci U S A 2003, 100:10878.
36. Ino Y., Yamazaki-Itoh R., Shimada K., Iwasaki M., Kosuge T., Kanai Y., et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 2013, 108:914.
37. Vizio B., Novarino A., Giacobino A., Cristiano C., Prati A., Ciuffreda L., et al. Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. Exp Ther Med 2012, 4:70.